The pharmaceutical sector is in an age characterized by speed, precision, regulatory complexity, and global competition. To remain competitive, organizations face increasing pressure to bring new therapies to market more quickly while also preserving the highest level of quality, compliance, and patient safety. In this environment, organizations achieve success through not only scientific breakthroughs but also the degree to which they are able to align Manufacturing, Clinical Development, Supply Chain, and Strategic Partnerships /Collaborations in the completion of their goals.
Disconnected operations cause pharmaceutical leaders to experience unnecessary costs and delays, risk, and inefficiencies. The pharmaceutical lifecycle consists of several stages, from sourcing critical materials to delivering smooth supplies for clinical trials to scaling commercial production. All of these stages should ideally work together cohesively.
This is where Integrated Pharmaceutical Strategies are differentiators. Companies that partner with 3rd party pharma contract manufacturing company for their active pharmaceutical ingredient (API) needs utilize advanced methods for clinical supply planning, develop strategic partner relationships, and utilize their expertise in application to position themselves as agile and resilient. Additionally, companies that utilize effective methods for comparator sourcing and specialized for comparator sourcing for clinical trials can also help ensure that their development programs remain on track and adhere to global regulatory protocols.
Through the remainder of this blog post, we will explore how pharmaceutical companies can build a synchronized ecosystem to support innovative active pharmaceutical ingredient contract manufacturing, expedite timelines, reduce operational risk, and develop long-term sustainable growth.
The New Reality of Pharmaceutical Development
In the past decade, drug development has changed tremendously. Advances in drug formulation techniques, along with new biologic and speciality drugs, have created a whole new set of challenges for pharmaceutical businesses beyond merely developing the drug.
Some of the top challenges include:
- Higher than expected development costs.
- Complex and strict regulatory requirements.
- Inconsistent supply chains.
- Increased global demand for clinical trials.
- Expectations for higher levels of quality assurance.
- Increased competition in the market and shorter timeframes to bring products to commercial use.
In response to these challenges, pharmaceutical companies are no longer using traditional operational models but are beginning to utilize collaborative ecosystems.
Pharmaceutical companies are no longer trying to do everything in-house; instead, they are forming partnerships with external companies that have specific expertise and can provide infrastructure to support pharmaceutical companies’ growth.
This will create new ways in which pharmaceutical companies will develop, manufacture and distribute products.
Why Strategic Collaboration Matters More Than Ever
In recent years, many pharmaceutical companies have begun using alternative ways to develop and manufacture their products. These new ways can help them meet their goals by providing them with access to talent and expertise that may not have been previously accessible internally.
With these new methods, pharmaceutical companies can accomplish the following:
- Fast and flexible access to scale up their production.
- More efficient operation and the ability to react to market changes.
- Access to lower production costs.
- Faster and easier navigation through a highly regulated environment.
- Quicker and easier access to expanding into new markets.
Cooperating in this way can help manage the manufacturing, clinical supply, and product sourcing requirements simultaneously.
Coordinating the activities described above in the best way often provides the best chance of meeting the project schedule or avoiding delays.
The Growing Importance of Active Pharmaceutical Ingredient Manufacturing Partnerships
The main component of all pharmaceutical products is the Active Pharmaceutical Ingredient (API). An API’s ability to be manufactured to an acceptable quality level requires advanced technical abilities, advanced manufacturing facilities, storage/distribution systems, and a rigorous quality control system.
As the pharmaceutical industry continues to refine its pharmaceutical innovations, more specific manufacturing requirements have contributed to the increasing demand for active pharmaceutical ingredient contract manufacturing.
There are multiple benefits associated with partnering with experienced manufacturers:
Advanced Manufacturing Capabilities
Generally, advanced manufacturing partners have advanced manufacturing technology with capabilities/products that aren’t available at the pharma contract manufacturing company plant.
Examples of these capabilities include:
- High-potency compound handling
- Advanced chemical synthesis processes
- Process improvements
- Scale-up support
- Advanced analytical testing capabilities
Increased Operational Efficiency
In order to operate a manufacturing facility at an optimal level, significant financial resources must be invested. By outsourcing the production of their products, companies can focus on developing and marketing their innovation.
Flexible Scalability
Pharmaceutical products typically experience short-term peaks and valleys in the demand cycle. As a result, companies will have the required flexibility from their manufacturing partner to help them develop a plan for scaling production based on the customer’s project requirements.
Advanced Regulatory Knowledge
Manufacturing partners that have extensive experience in producing pharmaceutical products have a thorough understanding of global regulatory requirements. As a result, these manufacturers have implemented compliance systems that are designed to enable access to international markets.
As a result, there is a more efficient path from development to commercialization for products.
Clinical Development Success Depends on Supply Reliability
The Clinical Trials process is a very important step within drug development. Delays during the Clinical Trials Stage can have large financial, pharmacist and revenue impacts that can hinder the development of new drugs.
One area that is often overlooked within Clinical Trials is the continuous availability of study materials. When there is a shortage of clinical trial supplies, the ability to enrol study patients will decrease and become delayed, Clinical Sites will become inactive and important Regulatory Milestones will be delayed.
As a result of the need for continuous availability of supplies, Pharmaceutical companies worldwide are making the development of a solid clinical supply plan a top strategic goal.
A successful clinical supply plan should include:
- Demand Forecasting
- Inventory Management
- Distribution Planning
- Regulatory Compliance
- Risk Mitigation
- Product Sourcing Coordination
Of all of these areas of activity, the procurement of comparators has been deemed to be a critical area of activity during the clinical supply planning process.
Understanding the Strategic Value of Comparator Sourcing
Investigational products must be compared to existing therapies or control/treatment arms in the majority of clinical trials, and as such, reference products play a pivotal role in producing meaningful clinical data.
However, obtaining comparator products often proves to be more difficult than many organizations originally anticipate. Effective comparator sourcing will become critical as a result. Comparator procurement encompasses identifying, obtaining, holding, and distributing reference medications in accordance with study requirements.
There are several common issues encountered in procuring comparator products, such as:
- Limited product availability
- Regional supply limitations
- Very complex regulatory requirements
- Concerns regarding the authenticity of products
- Variations in packaging
- Short shelf-life management
Without a sound sourcing strategy, clinical programs may be delayed in relation to their development timelines.
Institutions or organizations that place a preeminent focus on proactive planning may be better positioned to continue with their studies.
Comparator Sourcing for Clinical Trials: More Than Procurement
Comparator acquisition is not simply a buying process, yet many organizations wrongly believe that it is. Comparator sourcing for clinical trials requires specialized knowledge, precise coordination and planning.
Every clinical trial has specific specifications based on:
- Type of Study Design
- Geographic Location of Study
- Patient Population for Study
- Regulatory Requirements
- Availability of Product
- Storage Conditions
The comprehensive sourcing plan will address these factors while keeping the product intact throughout the supply chain.
Successful Comparator Sourcing Key Components
Product Verification
Authenticity cannot be compromised in clinical research, and therefore, every comparator must be verified before sourcing for the study. This will ensure compliance with the study protocol and the governing regulatory authorities.
Global Market Intelligence
Sourcing teams can identify opportunities and challenges related to limited inventory by understanding how product availability varies across regions.
Regulatory Compliance
Different countries have different import and distribution requirements, so understanding how to comply with them will ensure a smooth process for moving the product across borders.
Inventory Optimization
Proper inventory levels ensure that the product is not wasted and continues to be available without interruption.
Risk Management
By proactively planning for contingencies, organizations will reduce exposure to market interruptions and supply shortages.
When the comparator sourcing process is done effectively, it is a competitive advantage instead of just an operational challenge.
Building Agility Across the Pharmaceutical Value Chain
One of the most beneficial competitive advantages in today’s pharma operations is Agility.
Companies need to be able to change based on how quickly the following items change:
- Updates in regulations
- Market shifts & conditions
- Disruptions in the supply chain
- Fluctuations in demand
- Advancements in science
Manufacturing, sourcing, QA, logistics and Clinical Development Teams need to cooperate instead of working independently.
Using integrated decision-making provides transparency across an organization and can result in quicker turnaround times for addressing emerging issues.
This integrated method will assist in the ability to allocate resources more effectively and to make better strategic decisions.
Conclusion
The success potential for pharmaceutical companies will rely on more than just scientific discovery, but on their ability to develop operational ecosystems that are able to enable innovation from development through to commercialization. When organizations utilize individuals behind active pharmaceutical ingredient contract manufacturing, they receive benefits like access to specialized expertise, larger-scale production capabilities and improved efficiency through operation.
By accessing comparator sourcing and using effective comparator sourcing for clinical trials, companies have the ability to increase their chances of completing clinical development and complying with regulatory guidelines. Partnering with a proven pharma contract manufacturing company provides additional support for manufacturing efficiencies, and working with a qualified contract manufacturing consultant helps organizations work through complexities, assess risk and optimize their long-term strategic plans.
When manufacturing, sourcing, clinical supply and strategic planning collaborate together, pharmaceutical organizations can demonstrate increased levels of agility, resiliency and competitive advantage. As the pharmaceutical industry continues to evolve at a rapid pace, those organizations which are successful will be the ones that recognize the importance of operational integration as a foundational support of innovation, growth and patient impact.